Leerink Partners analyst maintains a Buy rating on Immunic (IMUX) with a $5.00 price target, citing favorable risk/reward profile for VidoCa in progressive multiple sclerosis. The Phase 2 CALLIPER study's potential to demonstrate positive trends in disability progression, despite not being powered for this endpoint, suggests promising therapeutic potential.
Immunic's Phase 3 ENSURE program for relapsing multiple sclerosis (RMS) continues as planned after a positive interim analysis by the Independent Data Monitoring Committee.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.